Concourse Financial Group Securities, Inc. Sigilon Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.64 Billion
  • Q3 2024

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$0.34 - $1.38 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$0.29 - $0.69 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$0.48 - $0.86 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$0.74 - $1.64 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$1.24 - $3.03 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$2.58 - $6.13 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$4.42 - $10.61 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$9.15 - $20.17 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$18.76 - $40.91 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021
BUY
$27.6 - $48.03 $0 - $0
0 New
0 $0

About Sigilon Therapeutics, Inc.

SGTX Quotes by TradingView
  • Ticker SGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,399,300
  • Description
  • Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...
More about SGTX
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email